EUVIMEDEUVIMED entdecken
Crossref

Effects of Elexacaftor/Tezacaftor/Ivacaftor on the Sinonasal Airspace in Cystic Fibrosis

Michelle H Kim iD, Nathan A Luzum, Adam J Kimple, Anna C Zemke, Dennis Frank-Ito iD

The Laryngoscope · 2026-02 · 136 (2) · 622-630

DOI: 10.1002/lary.70156 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Laryngoscope, online erschienen am 25.09.2025. Verfasst von Michelle H Kim und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Duke University, Durham, North Carolina, USA. Hauptthemen laut MEDLINE: Cystic Fibrosis, Aminophenols, Benzodioxoles, Quinolones. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Clinical and Translational Science Institute at the University of Pittsburgh, Cystic Fibrosis Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

People with Cystic Fibrosis ( CF ) experience significant sinonasal airway opacification, leading to chronic airway‐related conditions. The triple combination therapy Elexacaftor/Tezacaftor/Ivacaftor ( ETI ) has emerged as a therapeutic option for CF . This study uses volumetric quantification technique to evaluate changes in CF sinonasal airway patency pre‐ ETI and post‐ ETI .

Methods

Anatomically accurate person‐specific three‐dimensional sinonasal airspaces were reconstructed from radiographical images of 19 people (12 male, 7 female) with CF , pre‐ ETI and post‐ ETI . Sinonasal airspace surface area, volume, and surface‐area‐to‐volume ratio were calculated pre‐ ETI and post‐ ETI . Pre‐ ETI and post‐ ETI sinonasal airspace changes in these computed parameters were corrected with changes in both Lund‐Mackay and SNOT ‐22 scores.

Results

Median ( IQR ) surface area and volume increased significantly from pre‐ ETI (Surface Area: 251.97 cm 2 (43.71); Volume: 44.86 cm 3 (20.72)) to post‐ ETI (Surface Area: 295.77 cm 2 (31.34); Volume: 61.03 cm 3 (14.21)), with respective p < 0.01 per computed parameter. Furthermore, median surface‐area‐to‐volume ratio ( IQR ) was significantly different; pre‐ ETI : 0.053 cm −1 (0.007); post‐ ETI : 0.052 cm −1 (0.013); p = 0.04. Pre‐ ETI to post‐ ETI improvement changes in surface area and volume significantly correlated with corresponding changes in Lund‐Mackay scores (Surface Area: R = −0.78, p < 0.01; Volume: R = −0.68, p < 0.01), but correlated weakly with corresponding changes in patient‐reported SNOT ‐22 scores (Surface Area: R = −0.13, p = 0.62; Volume: R = −0.06, p = 0.82).

Conclusion

People with CF treated with ETI exhibited a significant increase in sinonasal airway patency, as evidenced by volumetric quantification analysis of surface area and volume differences. These increases in both parameters showed strong significant correlations with Lund‐Mackay scores; however, no such correlations were observed with SNOT ‐22 scores. Level of Evidence 4.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisAminophenolsBenzodioxolesQuinolonesIndolesParanasal SinusesPyrrolidinesPyridinesPyrazolesHumansMaleFemaleAdultDrug CombinationsYoung AdultAdolescentTomography, X-Ray ComputedTreatment OutcomeImaging, Three-DimensionalChloride Channel AgonistsQuinolines

Stichwörter der Autor:innen

Trikaftacystic fibrosiselexacaftor/tezacaftor/ivacaftornasal airwayvolumetric quantification

Substanzen

AminophenolsDrug CombinationsBenzodioxolesQuinolonesIndolesPyrrolidinesPyridinesPyrazoleselexacaftorivacaftor

Autor:innen und Institutionen

  • School of Medicine, Duke University, Durham, North Carolina, USA.
  • Department of Head and Neck Surgery & Communication Sciences, Duke University, Durham, North Carolina, USA.
  • Department of Otolaryngology-Head & Neck Surgery, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
  • Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Computational Biology & Bioinformatics PhD Program, Duke University, Durham, North Carolina, USA.
  • Department of Mechanical Engineering and Materials Science, Duke University, Durham, North Carolina, USA.

ORCID-Profile: Michelle H Kim, Dennis Frank-Ito

Förderung

  • Clinical and Translational Science Institute at the University of Pittsburgh
  • Cystic Fibrosis Foundation

Zitieren

APA

Kim, M. H., Luzum, N. A., Kimple, A. J., Zemke, A. C., & Frank-Ito, D. (2026). Effects of Elexacaftor/Tezacaftor/Ivacaftor on the Sinonasal Airspace in Cystic Fibrosis. The Laryngoscope, 136(2), 622-630. https://doi.org/10.1002/lary.70156

Vancouver

Kim MH, Luzum NA, Kimple AJ, Zemke AC, Frank-Ito D. Effects of Elexacaftor/Tezacaftor/Ivacaftor on the Sinonasal Airspace in Cystic Fibrosis. The Laryngoscope. 2026;136(2):622-630. doi:10.1002/lary.70156

BibTeX
@article{Kim2026,
  author = {Kim, Michelle H and Luzum, Nathan A and Kimple, Adam J and Zemke, Anna C and Frank-Ito, Dennis},
  title = {Effects of Elexacaftor/Tezacaftor/Ivacaftor on the Sinonasal Airspace in Cystic Fibrosis},
  journal = {The Laryngoscope},
  year = {2026},
  volume = {136},
  number = {2},
  pages = {622--630},
  doi = {10.1002/lary.70156}
}
Kostenlos starten →